Clinical Study

Predictive Value of Admission N-Terminal Pro-B-Type Natriuretic Peptide and Renal Function in Older People Hospitalized for Dyspnoea

Fabio Fabbian,1 Alfredo De Giorgi,1 Marco Pala,1 Stefano Volpato,2 Francesco Portaluppi,1 Giovanni Zuliani,2 and Roberto Manfredini1

1 Department of Medical Sciences, Section of Clinica Medica, Azienda Ospedaliera-Universitaria “S. Anna”, Ferrara, Italy
2 Department of Medical Sciences, Section of Internal Medicine, Gerontology, and Clinical Nutrition, Azienda Ospedaliera-Universitaria “S. Anna”, Ferrara, Italy

Correspondence should be addressed to Fabio Fabbian; f.fabbian@ospfe.it

Received 10 June 2013; Revised 1 October 2013; Accepted 3 October 2013

1. Introduction

N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) plasma levels are assessed in patients who present acutely with dyspnoea. NT-pro-BNP plasma levels are related to the severity of congestive heart failure (CHF) [1], and they are evaluated in order to diagnose CHF in older subjects aged 70 years [2]. Moreover, NT-pro-BNP levels have been found to predict incident disability in older people. In a recent Japanese study, participants were classified into five groups based on their NT-pro-BNP plasma levels (<47, 47–77, 77–133, 133–241, and >241 pg/mL, resp.), and the authors demonstrated that the combined rate of incident disability/death was higher in those with high NT-pro-BNP values [3]. Again, assessment of natriuretic peptide after myocardial infarction is a good indicator of infarct size and left ventricle function [4], probably due to its overexpression in the ischemic myocardium [5]. Nevertheless, not all patients with symptomatic CHF have high NT-pro-BNP plasma concentrations, and not all asymptomatic patients have low NT-pro-BNP values. Furthermore, plasma NT-pro-BNP provides prognostic information in patients with acute and chronic CHF and, in short-of-breath patients, it may be predictive of 1-year all-cause mortality independently of the baseline diagnosis of acute CHF [6]. Age, gender, and body mass index (BMI) are known determinants of NT-pro-BNP plasma levels, and the normal values tend to increase with age. We have previously shown that, in older people, diseases different from CHF affect NT-pro-BNP plasma levels [7], so that determination of NT-pro-BNP levels does not seem to help...
clinicians in definition of dyspnoea. Moreover, Vaes et al. [8] performed a systematic review to evaluate the diagnostic accuracy of natriuretic peptides in older subjects from the general population and found limited evidence supporting their use for diagnosis of cardiac dysfunction or heart failure.

The aim of this study was to investigate the relationship between NT-pro-BNP, glomerular filtration rate (GFR), comorbidities, and two-year all-cause mortality rates in a cohort of older people consecutively discharged from an internal medicine unit after admission for dyspnoea.

2. Methods

In the present study we evaluated with a two-year follow-up 134 patients, aged 65 to 90 years, previously enrolled in a cross-sectional study [7]. All these subjects had been admitted along a complete calendar year to our medical unit because of shortness of breath. They were suspected of having CHF and were studied with NT-pro-BNP assessment [7]; subjects with pulmonary infections and cancer were also included into the study. CHF was diagnosed according to the European Society of Cardiology criteria [9], and dyspnoea was assessed on the basis of Medical Research Council (MRC) breathlessness scale [10] plus the objective sign of increased use of respiratory accessory musculature. In particular, the study included only patients in grade 5 of the MRC breathlessness scale and those with evidence of increasing use of respiratory accessory musculature, whereas subjects with pulmonary embolism were excluded. Age, sex, body mass index (BMI), and serum creatinine were recorded at the time of admission. Serum creatinine levels assays were all performed with the Jaffe method on a Hitachi Modular (Roche Diagnostics, Mannheim, Germany). Renal function was also assessed as GFR evaluated by CKD-EPI formula [11]; patients were classified into the five stages of chronic kidney disease (CKD) [12]. GFR < 60 mL/min/1.73 m² defined impaired renal function [12]. As regards comorbidities, history of hypertension, diabetes mellitus, ischaemic heart disease, CHF, cerebrovascular disease, peripheral vascular disease, and chronic obstructive pulmonary disease were considered.

As for NT-pro-BNP plasma levels, patients were classified into subgroups, according to the Januzzi cut-off levels (i.e., age < 50 years: upper normal value 450 pg/mL; age 50–75 years: upper normal value 900 pg/mL; age > 75 years: upper normal value 1,800 pg/mL) [13].

This cohort of patients was followed up for 779 ± 370 days (maximum 1181 days). Cases of inhospital death were excluded, and the rate of death from all causes occurring after discharge was determined. Out of 134 patients, 119 were discharged alive from hospital and were included in the follow-up.

The study was approved by the local ethics committee.

2.1. Statistical Analysis. The results are presented as mean ± SD or percentage as appropriate. NT-pro-BNP values were log transformed [Ln (NT-pro-BNP)] prior to the analysis, in order to approximate normal distribution. Patients were classified into the deceased and survivors, and clinical parameters were compared in the two groups by t-test, chi-squared test, and Mann-Whitney U test, as appropriate. Survival analysis of parameters independently associated with all-cause mortality was performed by Kaplan-Meier survival curve, by classifying the patients on the basis of GFR (<60 and ≥60 mL/min/1.73 m²) and NT-pro-BNP plasma levels (normal and high). A value of P < 0.05 was considered statistically significant. Because of the limited absolute number of events (35 deaths) and in order to avoid an overparameterized model, Cox regression analysis, with a backward stepwise selection method to eliminate unnecessary control variables, was carried out to evaluate the effect of the biochemical and clinical variables for all-cause mortality, and hazard ratios (HR) were calculated. SPSS for Windows was used as a statistical system (SPSS, version 13, SPSS Inc., Chicago, IL, USA).

3. Results

We analyzed 119 patients aged 79 ± 6 years (70, 58.8% females; 49, 41.2% males). Hypertension was diagnosed in 67.2% of cases, diabetes mellitus in 36.1%, ischaemic heart disease in 36.1%, CHF in 30.3%, chronic obstructive pulmonary disease in 23.5%, peripheral vascular disease in 25.2%, and cerebrovascular disease in 19.3%. Mean BMI was 28 ± 7 kg/m², serum creatinine 1.32 ± 0.63 mg/dL, GFR 52 ± 21 mL/min/1.73 m², and NT-pro-BNP 5.576 ± 8.638 pg/mL (range 60–56,829). Mean Ln (NT-pro-BNP) was 3.37 ± 0.64. Classification of patients based on GFR levels showed that 8 (6.7%) were in CKD stage 1, 34 (28.6%) in CKD stage 2, 57 (47.9%) in CKD stage 3, 18 (15.1%) in CKD stage 4 and 2 (1.7%) in CKD stage 5. Thirty-five (29.4%) patients died after a followup of 266 ± 251 days. The main clinical parameters of the deceased and survivors are shown in Table 1. Cardiovascular therapy administered during admission in deceased and survivors was not statistically different (data not shown). Similarly, the percentage of the deceased and survivors treated with ace inhibitors and angiotensin receptor blockers was not statistically different (34.3 versus 51.2% and 8.6 versus 11.9%, resp.). Multivariate Cox proportional regression analysis (backward selection model) showed that only GFR (HR: 0.969, 95%CI: 0.950–0.988; P = 0.001) and Ln (NT-pro-BNP) (HR: 2.360, 95%CI: 1.208–4.610; P = 0.012) were predictors of total mortality. Other variables initially forced in the survival model (age, sex, history of hypertension diabetes, CHF, ischaemic heart disease, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, and cardiovascular therapy) were not statistically associated with the risk of death over the follow-up.

Figure 1 shows the survival analysis of subjects with NT-pro-BNP lower or higher than Januzzi cut-off levels (P = 0.05), and Figure 2 shows the cumulative survival in patients with GFR (<60 and ≥60 mL/min/1.73 m²) and normal or high NT-pro-BNP. Patients characterized by high NT-pro-BNP levels and normal renal function showed a dramatic
Table 1: Main clinical parameters of the deceased and survivors.

| Parameter                        | The deceased | Survivors     | P   |
|----------------------------------|--------------|---------------|-----|
| Age (years) at admission         | 81 ± 5       | 79 ± 6        | 0.070 |
| BMI (Kg/m²)                      | 27 ± 6       | 28 ± 7        | 0.573 |
| Serum creatinine (mg/dL)         | 1.66 ± 0.79  | 1.18 ± 0.49   | <0.001 |
| GFR (mL/min/1.73 m²)             | 39.8 ± 18.4  | 57.1 ± 20.4   | <0.001 |
| NT-pro-BNP (pg/mL)               | 9809 ± 13113 | 3812 ± 4995   | 0.004 |
| Ln (NT-pro-BNP)                  | 3.66 ± 0.58  | 3.24 ± 0.62   | 0.001 |
| Follow-up (days)                 | 266 ± 251    | 992 ± 111     | <0.001 |
| Diabetes (n (%))                 | 14 (40)      | 29 (34.5)     | 0.571 |
| Pulmonary disease (n (%))        | 13 (37.1)    | 15 (17.9)     | 0.024 |
| Congestive heart failure (n (%)) | 12 (34.2)    | 24 (28.6)     | 0.536 |
| Cerebrovascular events (n (%))   | 8 (22.9)     | 10 (11.9)     | 0.129 |
| Peripheral vascular disease (n (%)) | 11 (31.4)   | 19 (22.6)     | 0.313 |
| Ischaemic heart disease (n (%))  | 17 (48.6)    | 26 (30.9)     | 0.068 |

Figure 1: Cumulative survival curves in patients with NT-pro-BNP lower and higher than Januzzi cut-off levels.

Figure 2: Cumulative survival curves in patients with combined different degrees of renal function (GFR < 60 or > 60 mL/min/1.73 m²) and normal or high NT-pro-BNP.

4. Discussion

We found that, in a cohort of older people hospitalized for dyspnoea, GFR < 60 mL/min/1.73 m² and high NT-pro-BNP levels measured at admission were independently associated with total mortality rate after two years of follow-up. Nevertheless, when these two parameters were combined, only NT-pro-BNP values above the Januzzi cut-off levels had a significant impact on survival.

It has been shown that discharge levels of NT-pro-BNP predict poor cardiovascular outcome in hospitalized diabetic patients with a broad spectrum of cardiovascular disease [14]. Again, NT-pro-BNP levels are strong and independent predictors for long-term mortality in unselected dyspnoeic patients presenting to the emergency department, independent of the cause of dyspnoea [15]. In patients with advanced left ventricular dysfunction, the relationship between NT-pro-BNP and mortality is known since more than one decade [16]. Moreover, in subjects with advanced CHF, natriuretic peptide is a powerful predictor of functional status deterioration [17] and an independent predictor of sudden death [18]. Recently, Idris et al. [19] suggested that high NT-pro-BNP plasma levels, determined in the acute phase of stroke, were an important predictor of mortality. In patients with CHF, it has been estimated that every 100 pg/mL increase in plasma natriuretic peptide was associated with a 35 percent increase in the relative risk of death [20].

In short-of-breath patients, NT-pro-BNP may be predictive of 1-year all-cause mortality, independently of the baseline diagnosis of acute heart failure [6]. In fact, mortality was higher in patients with baseline NT-pro-BNP concentrations above the cut-off levels of 2060 ng/L [21]. The correlation between NT-pro-BNP and mortality has been confirmed also by long-term studies. Data on a cohort of older people with
symptoms of CHF, followed in primary health care, showed that high NT-pro-BNP plasma concentrations, together with diabetes and New York Heart Association class III, were predictors of cardiovascular mortality up to 10 years [22]. Again, a prospective study on more than 3500 men (aged 60–79 years) followed for 9 years, including records on all major cardiovascular disease events (i.e., fatal and nonfatal coronary heart disease, stroke, and cardiovascular death), showed that NT-pro-BNP was more strongly associated with outcomes than C-reactive protein in subjects with and without preexisting cardiovascular disease. Moreover, the raise of NT-pro-BNP was strongly associated with GFR [23].

The relationship between renal function and NT-pro-BNP represents pivotal question, since NT-pro-BNP undergoes renal clearance, and a decreased GFR is associated with increased NT-pro-BNP levels. Thus, both GFR and NT-pro-BNP could represent risk factors for increased mortality. Reny et al. [24] assessed NT-pro-BNP in 254 patients over 70 years hospitalized because of dyspnoea, and kidney function was evaluated with Cockcroft-Gault formula. Fifty-five percent of patients died, and the median survival was about 750 days. Cox analysis showed that NT-pro-BNP higher than 2856 pg/mL, creatinine clearance lower than 30 mL/min, and age higher than 80 years were predictors of all-cause mortality [24]. In patients with end-stage renal disease, in spite of generally elevated NT-pro-BNP levels, the latter remains an independent predictor of mortality [25].

5. Limitations

The analysis considering only all-cause mortality, and not cardiovascular mortality as a separate outcome, represents a first limitation. Nevertheless, the small number of patients did not allow further multiple grouping. Moreover, since cardiovascular treatment in the deceased and survivors was not significantly different, a certain degree of homogeneity may be hypothetically presumed. Second, dyspnoea is usually associated with an acute condition, and renal function evaluated by equations would require clinically stable conditions. In our study, we decided to exclude patients with acute kidney injury, since they are more likely to die during hospitalization. Third, in our study we did not systematically consider cardiac function in all patients. On the other hand, Lee et al. [26] reported that NT-pro-BNP values progressively increase with worsening renal function, independent of the value of ejection fraction. We are aware that it is somewhat difficult to draw conclusions about CKD stage 5, due to the very limited number of such patients enrolled in our study. Thus, data should be taken with caution, but this study was focused on the real world of elderly comorbid subjects admitted to internal medicine wards, also because patients with severe CKD on stage 5 are usually managed by nephrologic units. Fourth, we did not consider urine abnormalities and imaging studies for classification of CKD stages. However, in our opinion this approach is more appropriate for stable patients managed into ambulatory setting, since it is difficult to correctly classify CKD in acute patients, especially when GFR is higher than 60 mL/min/1.73 m². Finally, not being strictly related to the aims of our study, we did not assess systematically functional and cognitive status of the patients; these parameters might have influenced the development of diseases which may give dyspnoea as main clinical symptom.

Study strengths included well-defined and precise parameters of evaluation of NT-pro-BNP and renal function. As for the former, in fact, high NT-pro-BNP plasma levels were defined on the basis of the internationally validated Januzzi cut-off levels [13]. Moreover, we measured serum creatinine with a standardized method and estimated GFR with a validated equation. In fact, the choice of the formula used to assess renal function is not a secondary point, especially when such assessment is used to make long-term evaluations of different diseases [27]. A recent cross-sectional study on a cohort of older people with and without cognitive impairment reported significant differences in the evaluation of GFR with different equations [28]. Again, Earley et al. [29] reviewed the performance of GFR estimating equations derived or reexpressed and validated by using creatinine measurement traceable to the standard reference material and concluded that, in a general practice and public health perspective, the CKD-EPI equation represents the best instrument. The same consideration was reported by Corsonello et al. [30], after a multicentre observational study on more than ten thousand hospitalized older people, who were evaluated for their incident adverse drug reactions during hospital stay and for ability of different equations to calculate GFR. In a previous study, we analyzed the relationship between NT-pro-BNP and kidney function and found that reduced renal function may correspond to increased NT-pro-BNP concentrations, and this could represent an interfering factor when high NT-pro-BNP plasma levels are to be interpreted. Moreover, the different formulae used to evaluate GFR could differently stratify NT-pro-BNP in older adults [31].

6. Conclusions

In conclusion, we found that, in a cohort of older comorbid patients consecutively hospitalized for shortness of breath (representative of the real world of everyday patients of internal medicine wards), admission renal function and NT-pro-BNP were independently associated with long-term mortality. In particular, subjects with high NT-pro-BNP and GFR ≥ 60 mL/min/1.73 m² exhibited a reduced survival of about 20% compared with the other groups. In these subjects, elevated admission NT-pro-BNP levels could represent an important predictor of mortality.

Disclosure

This study has been supported, in part, by a scientific grant (FAR: Fondo Ateneo Ricerca) from the University of Ferrara, Italy. The funding source had no involvement in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.
References

[1] A. J. de Bold, B. G. Bruneau, and M. L. K. de Bold, “Mechanical and neuroendocrine regulation of the endocrine heart,” Cardiovascular Research, vol. 31, no. 1, pp. 7–18, 1996.

[2] I. Oudejans, A. Mosterd, N. P. A. Zuinthoff, and A. W. Hoes, “Applicability of current diagnostic algorithms in geriatric patients suspected of new, slow onset heart failure,” Age and Ageing, vol. 41, no. 3, Article ID afg181, pp. 309–316, 2012.

[3] A. Hozawa, Y. Sugawara, Y. Tomata et al., “Relationships between n-terminal pro b-type natriuretic peptide and incident disability and mortality in older community-dwelling adults: the Tsurugaya study,” Journal of the American Geriatrics Society, vol. 58, no. 12, pp. 2439–2441, 2010.

[4] P. Kleczyński, J. Legutko, T. Rakowski et al., “Predictive utility of NT-pro BNP for infarct size and left ventricle function after acute myocardial infarction in long-term follow-up,” Disease Markers, vol. 34, no. 3, pp. 199–204, 2013.

[5] A. Surdacki, E. Marewicz, T. Rakowski et al., “Coincidence of moderately elevated N-terminal pro-B-type natriuretic peptide, endothelial progenitor cells deficiency and propensity to exercise-induced myocardial ischemia in stable angina,” Disease Markers, vol. 28, no. 2, pp. 101–114, 2010.

[6] A. Gegenhuber, T. Mueller, B. Dieplinger, W. Poelz, R. Pacher, and M. Haltmayer, “B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure,” Clinica Chimica Acta, vol. 370, no. 1-2, pp. 174–179, 2006.

[7] F. Fabbian, A. de Giorgi, M. Pala, R. Tiseo, and F. Portaluppi, “Elevated NT-proBNP levels should be interpreted in elderly patients presenting with dyspnea,” European Journal of Internal Medicine, vol. 22, no. 1, pp. 108–111, 2011.

[8] B. Vaes, W. de Ruijter, J. Gussakloo, and J. Degryse, “The accuracy of plasma natriuretic peptide levels for diagnosis of cardiac dysfunction and chronic heart failure in community-dwelling elderly: a systematic review,” Age and Ageing, vol. 38, no. 6, pp. 655–662, 2009.

[9] K. Dickstein, A. Cohen-Solal, G. Filippatos et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008,” European Heart Journal, vol. 29, pp. 2388–2442, 2008.

[10] C. Stenton, “The MRC breathlessness scale,” Occupational Medicine, vol. 58, no. 3, pp. 226–227, 2008.

[11] A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009.

[12] National Kidney Foundation, “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 36, supplement 1, pp. S1–S266, 2002.

[13] J. L. Januzzi Jr., “Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure,” Cleveland Clinic Journal of Medicine, vol. 73, no. 2, pp. 149–157, 2006.

[14] R. Pfister, D. Tan, J. Thekkanal, M. Hellmich, E. Erdmann, and C. A. Schneider, “NT-pro-BNP measured at discharge predicts outcome in multimorbid diabetic inpatients with a broad spectrum of cardiovascular disease,” Acta Diabetologica, vol. 44, no. 2, pp. 91–97, 2007.

[15] M. Christ, A. Thuerlimann, K. Laule et al., “Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea,” European Journal of Clinical Investigation, vol. 37, no. 11, pp. 834–841, 2007.

[16] B. Stanek, B. Frey, M. Hülsmann et al., “Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction,” Journal of the American College of Cardiology, vol. 38, no. 2, pp. 436–442, 2001.

[17] J. Koglin, S. Pehlivanli, M. Schwablmaier, M. Vogeser, P. Cremer, and W. VonScheidt, “Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure,” Journal of the American College of Cardiology, vol. 38, no. 7, pp. 1934–1941, 2001.

[18] R. Berger, M. Huelsman, K. Streekker et al., “B-type natriuretic peptide predicts sudden death in patients with chronic heart failure,” Circulation, vol. 105, no. 20, pp. 2392–2397, 2002.

[19] I. Idris, R. Hill, I. Ross, and J. C. Sharma, “N-terminal probrain natriuretic peptide predicts 1-year mortality following acute stroke: possible evidence of occult cardiac dysfunction among patients with acute stroke,” Age and Ageing, vol. 39, no. 6, Article ID afg098, pp. 752–755, 2010.

[20] J. A. Doust, E. Pietrzak, A. Dobson, and P. P. Glasziou, “How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review,” British Medical Journal, vol. 330, no. 7492, pp. 625–627, 2005.

[21] A. Gegenhuber, T. Mueller, B. Dieplinger, W. Poelz, R. Pacher, and M. Haltmayer, “B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure,” Clinica Chimica Acta, vol. 370, no. 1-2, pp. 174–179, 2006.

[22] U. Alehagen and U. Dahlström, “Can NT-proBNP predict risk of cardiovascular mortality within 10 years? Results from an epidemiological study of elderly patients with symptoms of heart failure,” International Journal of Cardiology, vol. 133, no. 2, pp. 233–240, 2009.

[23] S. G. Wannamethee, P. Walsh, G. D. Lowe et al., “N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease,” Journal of the American College of Cardiology, vol. 58, no. 1, pp. 56–64, 2011.

[24] J.-L. Reny, O. Millot, T. Vandercam et al., “Admission NT-proBNP levels, renal insufficiency and age as predictors of mortality in elderly patients hospitalized for acute dyspnea,” European Journal of Internal Medicine, vol. 20, no. 1, pp. 14–19, 2009.

[25] M. Svensson, A. Gorst-Rasmussen, E. B. Schmidt, K. A. Jorgensen, and J. H. Christensen, “NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease,” Clinical Nephrology, vol. 71, no. 4, pp. 380–386, 2009.

[26] J. E. Lee, S. Y. Choi, W. Huh et al., “N-terminal pro-brain natriuretic peptide levels predict left ventricular systolic function in patients with chronic kidney disease,” Journal of Korean Medical Science, vol. 24, supplement 1, pp. S63–68, 2009.

[27] F. Fabbian, M. Pala, and R. Manfredini, “Intensive therapy and GFR in type 1 diabetes,” The New England Journal of Medicine, vol. 356, no. 9, pp. 856–857, 2012.

[28] K. Alagiakrishnan and A. Senthilvelan, “Comparison of chronic kidney disease (CKD) epidemiology formula with other calculated creatinine formulas for the determination of CKD in cognitively intact and impaired elderly outpatients,”

Disease Markers 739
Journal of the American Geriatrics Society, vol. 60, no. 6, pp. 1181–1183, 2012.

[29] A. Earley, D. Miskulin, E. J. Lamb, A. S. Levey, and K. Uhlig, "Estimating equations for glomerular filtration rate in the era of creatinine standardization. A systematic review," Annals of Internal Medicine, vol. 156, no. 11, pp. 785–795, 2012.

[30] A. Corsonello, C. Pedone, F. Lattanzio, G. Onder, and R. Antonelli Incalzi, "Association between glomerular filtration rate and adverse drug reactions in elderly hospitalized patients: the role of the estimating equation," Drugs and Aging, vol. 28, no. 5, pp. 379–390, 2011.

[31] F. Fabbian, A. de Giorgi, F. Portaluppi, and G. Zuliani, "Relationship between N-terminal pro-B-type natriuretic peptide plasma levels and renal function evaluated with different formulae in older adult subjects admitted because of dyspnea," Gerontology, vol. 58, no. 1, pp. 50–55, 2011.